Alterity Therapeutics (ASX:ATH) Current Accrued Expense: A$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ATH Alterity Therapeutics Ltd ASX:ATH
25 GF Score
Price A$0.56
View Full Analysis

What is Alterity Therapeutics Current Accrued Expense?

Alterity Therapeutics ASX:ATH -5.08% 25 Current Accrued Expense is A$0.00 Mil as of Mar. 2026. GuruFocus rates ASX:ATH with a GF Score™ of 25/100.

Alterity Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2026 was A$0.00 Mil.

Alterity Therapeutics's annual Current Accrued Expense increased from Jun. 2023 (A$1.77 Mil) to Jun. 2024 (A$4.02 Mil) but then declined from Jun. 2024 (A$4.02 Mil) to Jun. 2025 (A$2.02 Mil).

Alterity Therapeutics Current Accrued Expense Related Terms

Alterity Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Current Accrued Expense Chart

Alterity Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.77 4.02 2.02 0.00

Alterity Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.02 0.00 0.00 0.00 0.00
ASX:ATH
25GF Score
Alterity Therapeutics Ltd ASX:ATH
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of A$0.00 Mil mean?
Alterity Therapeutics (ASX:ATH) has a Current Accrued Expense of A$0.00 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Current Accrued Expense too high?
Alterity Therapeutics' current Current Accrued Expense is A$0.00 Mil. Overall, Alterity Therapeutics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Current Accrued Expense compare to VRTX and REGN?
Alterity Therapeutics' Current Accrued Expense of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current Current Accrued Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Current Accrued Expense of A$0.00 Mil. The current Current Accrued Expense is A$0.00 Mil. Alterity Therapeutics' overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Current Accrued Expense is A$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
25GF Score

Get the complete analysis for ASX:ATH

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.56
Price